SCHEMBL13656741

SCHEMBL13656741

CCCCC(=O)c1cccc2c(C(=O)CCCC)cccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.54
GABRB2 P47870 1/20 0.54
HTT P42858 5/20 0.49
MAPT P10636 4/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 3/20 0.49
LMNA P02545 3/20 0.49
KDM4E B2RXH2 3/20 0.49
GMNN O75496 2/20 0.49
POLB P06746 2/20 0.49
HPGD P15428 2/20 0.49
MAPK1 P28482 2/20 0.49
BLM P54132 2/20 0.49
PMP22 Q01453 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
CMKLR1 Q99788 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
CYP2C9 P11712 2/20 0.49
TSHR P16473 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29875233 0.89 ALDH1A1 (0.64) GABRA1GABRB2HTTMAPTMEN1
SCHEMBL2843776 0.89 ALDH1A1 (0.64) GABRA1GABRB2HTTMAPTMEN1
SCHEMBL29875304 0.87 KDM4E (0.54) GABRA1GABRB2MAPTMEN1KMT2A
SCHEMBL27952677 0.87 KDM4E (0.54) GABRA1GABRB2MAPTMEN1KMT2A
SCHEMBL30125359 0.85 GABRA1 (0.54) GABRA1GABRB2HTTMAPTMEN1
SCHEMBL83892 0.85 GABRA1 (0.54) GABRA1GABRB2HTTMAPTMEN1
SCHEMBL10603909 0.84 HSD17B3 (0.53) GABRA1GABRB2HTTMAPTMEN1
SCHEMBL9857065 0.84 MEN1 (0.62) HTTMAPTMEN1KMT2AALDH1A1
SCHEMBL15732279 0.83 MEN1 (0.60) HTTMAPTMEN1KMT2AALDH1A1
SCHEMBL15659633 0.83 MEN1 (0.60) HTTMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605182-B2 drug conjugate with a marker for imaging to detect by fluorescence, X-ray, computerized tomography, magnetic resonance imaging (MRI), radio-isotope scan, single photon emission tomography (SPECT) or positron emission tomography (PET scan); targeting anticancer drugs to the tumor in body APOSENSE LTD. (IL) 2009-10-20 US disclosed
US-7605182-B2 drug conjugate with a marker for imaging to detect by fluorescence, X-ray, computerized tomography, magnetic resonance imaging (MRI), radio-isotope scan, single photon emission tomography (SPECT) or positron emission tomography (PET scan); targeting anticancer drugs to the tumor in body APOSENSE LTD. (IL) 2009-10-20 US disclosed
US-20070031326-A1 Compounds that selectively bind to membranes of apoptotic cells NEUROSURVIVAL TECHNOLOGIES, LTD. (IL) 2007-02-08 US disclosed
US-20070031326-A1 Compounds that selectively bind to membranes of apoptotic cells NEUROSURVIVAL TECHNOLOGIES, LTD. (IL) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070031326-A1 Compounds that selectively bind to membranes of apoptotic cells BAD, BID, MCL1 GABRA1 3955/4885GABRB2 3333/4885HTT 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.